Hematology

The first 2 participants dosed are free of vaso-occlusive events as of 5 and 1.5 months of follow-up after treatment with EDIT-301.

Ivan Horak, MD, discussed Tessa’s cell therapy platforms and the ACTION clinical trial.

Patients with non-Hodgkin lymphoma in Nkarta's phase 1 study had a 75% complete response rate.

The associate professor from the Medical College of Wisconsin discussed how to address unmet needs with CAR T-cell therapies.

Beam Therapeutics provided data on genomic rearrangement, off-target edits and from a cytokine independent growth assay to the FDA in November 2022.

Review top news and interview highlights from the week ending December 2, 2022.

Updated data from 3 of the company’s programs were presented at an R&D showcase.

There was no significant difference in OS and CR rate for patients based on household poverty and neighborhood opportunity.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has decided not to hold an advisory committee meeting for Roctavian after all.

CB-010 most recently demonstrated a 100% complete response rate in data presented at the EHA 2022 congress.

BEAM-101 is edited with a next-generation CRIPSR product to mimic single nucleotide polymorphisms that enable persistence of fetal hemoglobin.

Shebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.

Paul discussed common symptoms and typical treatments for the 2 adverse events.

The study has now dosed 8 patients in total.

Review top news and interview highlights from the week ending November 25, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A marketing authorization application for etranacogene dezaparvovec is currently under review by the EMA.

Omidubicel’s BLA was originally accepted for priority review in August of this year.

Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.

The phase 1 clinical trial plans to initiate enrollment in early 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ExCellThera is in the process of the expanding the studies into new trial sites in the United States and Europe.

The Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.

Review top news and interview highlights from the week ending November 11, 2022.